Monte Rosa Therapeutics Files 8-K

TL;DR

Monte Rosa Therapeutics signed a material definitive agreement on Oct 25th.

AI Summary

On October 25, 2024, Monte Rosa Therapeutics, Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offices in Boston, MA, filed this 8-K report on October 28, 2024. The filing pertains to the company's business operations in biological products.

Why It Matters

This filing indicates a significant event for Monte Rosa Therapeutics, Inc., likely involving a new contract or partnership that could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that may affect the company's stock price and future prospects.

Key Players & Entities

• Monte Rosa Therapeutics, Inc. (company) — Registrant
• October 25, 2024 (date) — Date of earliest event reported
• October 28, 2024 (date) — Date of report filing
• 321 Harrison Avenue, Suite 900 Boston, MA 02118 (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share GLUE The Nasdaq
• $150 m — from Novartis (1) an upfront payment of $150 million, (2) up to $2.1 billion in develo
• $2.1 billion — ront payment of $150 million, (2) up to $2.1 billion in development, regulatory, and sales m
• $1.5 billion — egulatory milestone payments, exceeding $1.5 billion if multiple indications achieve regulat

Filing Documents

• glue-20241025.htm (8-K) — 51KB
• glue-ex99_1.htm (EX-99.1) — 23KB
• img106802192_0.jpg (GRAPHIC) — 12KB
• 0000950170-24-117567.txt ( ) — 220KB
• glue-20241025.xsd (EX-101.SCH) — 30KB
• glue-20241025_htm.xml (XML) — 5KB

01. Entry into a Material Definitive Agreement

Item 1.01. Entry into a Material Definitive Agreement On October 25, 2024, Monte Rosa Therapeutics AG ("Monte Rosa AG," hereinafter the "Company"), a whollyowned subsidiary of Monte Rosa Therapeutics, Inc. and Novartis Pharma AG ("Novartis") entered into a License Agreement (the "Agreement"). Pursuant to the Agreement, the Company will grant to Novartis an exclusive, royalty-bearing, sublicensable and transferable license to develop, manufacture, and commercialize VAV1 molecular glue degraders ("MGDs"), including MRT-6160, which is currently in Phase 1 clinical development for immune-mediated conditions. The Company is responsible for completing the ongoing Phase 1 clinical study and Novartis is responsible for all subsequent development and commercial activities starting at Phase 2. Development and commercial activities governed by the Agreement will be overseen by a Development Committee and a Commercialization Committee. Pursuant to the Agreement, the Company is entitled to receive from Novartis (1) an upfront payment of $150 million, (2) up to $2.1 billion in development, regulatory, and sales milestones, beginning upon initiation of Phase 2 studies including (a) potential development and regulatory milestone payments, exceeding $1.5 billion if multiple indications achieve regulatory approval in multiple territories, (b) potential sales milestones payments in connection with sales outside of the United States, and (3) tiered royalties on sales outside of the United States. The Company will continue to be responsible for costs associated with the ongoing Phase 1 clinical study and Novartis will be responsible for costs associated with any subsequent clinical studies. The Company and Novartis also agreed to a net profit and loss sharing arrangement, pursuant to which the Company will co-fund any global clinical development from Phase 3 onwards and will share 30% of any profits and losses associated with the manufacturing and commercialization of the licensed p

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure On October 28, 2024, the Company issued a press release announcing its entry into the Agreement. A copy of the press release is furnished hereto as Exhibit 99.1. The information in Item 7.01 of this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form8-K contains "forward-looking statements" of the Company within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including without limitation, express or implied statements regarding expectations regarding the closing of the transaction with Novartis, the receipt of upfront, milestone and other payments under the Agreement, the future development and commercialization of VAV1 MGDs, including MRT-6160. Any forward-looking statements in this Current Report on Form8-K are based on management's current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent annual report on Form 10-K as well as discussions of potential risks, uncertainties, and other important factors in the Company's other and subsequent filings with the Securities and Exchange Commission. All information in this Current Report on Form8-K is as of the date of this Current Report on Form 8-K, and the Company undertakes no duty to update this information unless required by law.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits (d) Exhibits 99.1 Press Release issued by Monte Rosa Therapeutics, Inc. dated October 28, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Monte Rosa Therapeutics, Inc. Date: October 28, 2024 By: /s/ Markus Warmuth Markus Warmuth President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR